Clinical Trials Logo

Familial Cold Urticaria clinical trials

View clinical trials related to Familial Cold Urticaria.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00288704 Completed - Clinical trials for Genetic Diseases, Inborn

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

Start date: December 2005
Phase: Phase 3
Study type: Interventional

Inflammatory symptoms of Cryopyrin-Associated Periodic Syndrome (CAPS) are due to mutations in a the NLRP-3 gene (previously known as Cold Induced Autoinflammatory Syndrome-1 or CIAS1). These mutations result in the body's overproduction of interleukin-1 (IL-1), a protein that stimulates the inflammatory process. IL-1 Trap (rilonacept) was designed to bind to the interleukin-1 cytokine and prevent it from binding to its receptors in the body.

NCT ID: NCT00214851 Completed - Clinical trials for Familial Cold Urticaria

The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria

Start date: September 2005
Phase: Phase 1
Study type: Interventional

An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four week period in the treatment of Familial Cold Urticaria. Familial Cold Urticaria (FCU) is a rare autosomal dominant condition manifesting symptoms triggered by exposure to cold and variable in expression. Currently there is no standard reliable agent available for the treatment of patients with FCU.This study will evaluate the efficacy of Kineret (anakinra), an interleukin 1 receptor antagonist in induction and maintenance therapy in patients with FCU.